Literature DB >> 21484384

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

George Sgouros1, Robert F Hobbs, Francis B Atkins, Douglas Van Nostrand, Paul W Ladenson, Richard L Wahl.   

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, (124)I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of (124)I PET/CT on thyroid cancer therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21484384      PMCID： PMC3172686          DOI： 10.1007/s00259-011-1769-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  32 in total

Review 1.  Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy.

Authors:  Roger Dale
Journal:  Cancer Biother Radiopharm       Date:  2004-06       Impact factor: 3.099

2.  Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides.

Authors:  G Sgouros; G Barest; J Thekkumthala; C Chui; R Mohan; R E Bigler; P B Zanzonico
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

Review 3.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

4.  Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.

Authors:  H R Maxon; E E Englaro; S R Thomas; V S Hertzberg; J D Hinnefeld; L S Chen; H Smith; D Cummings; M D Aden
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

5.  A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system.

Authors:  M Tagesson; M Ljungberg; S E Strand
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

6.  In vivo quantitation of lesion radioactivity using external counting methods.

Authors:  S R Thomas; H R Maxon; J G Kereiakes
Journal:  Med Phys       Date:  1976 Jul-Aug       Impact factor: 4.071

7.  A comprehensive three-dimensional radiation treatment planning system.

Authors:  R Mohan; G Barest; L J Brewster; C S Chui; G J Kutcher; J S Laughlin; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

8.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

Authors:  R G Dale
Journal:  Br J Radiol       Date:  1985-06       Impact factor: 3.039

9.  Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia.

Authors:  K S Kolbert; K A Hamacher; J G Jurcic; D A Scheinberg; S M Larson; G Sgouros
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

10.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.

Authors:  George Sgouros; Katherine S Kolbert; Arif Sheikh; Keith S Pentlow; Edward F Mun; Axel Barth; Richard J Robbins; Steven M Larson
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057
View more
  10 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

2.  Effects of Dosimetrically Guided I-131 Therapy on Hematopoiesis in Patients With Differentiated Thyroid Cancer.

Authors:  Athanasios Bikas; Mark Schneider; Sameer Desale; Frank Atkins; Mihriye Mete; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  J Clin Endocrinol Metab       Date:  2016-02-22       Impact factor: 5.958

3.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

4.  Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.

Authors:  Donika Plyku; Esther Mena; Steven P Rowe; Martin A Lodge; Zsolt Szabo; Steve Y Cho; Martin G Pomper; George Sgouros; Robert F Hobbs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

5.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.

Authors:  Donika Plyku; Robert F Hobbs; Kevin Huang; Frank Atkins; Carlos Garcia; George Sgouros; Douglas Van Nostrand
Journal:  J Nucl Med       Date:  2017-01-19       Impact factor: 10.057

6.  VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4.

Authors:  Susan D Kost; Yuni K Dewaraja; Richard G Abramson; Michael G Stabin
Journal:  Cancer Biother Radiopharm       Date:  2015-01-16       Impact factor: 3.099

7.  Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma.

Authors:  Manuel Weber; Jochen Schmitz; Ines Maric; Kim Pabst; Lale Umutlu; Martin Walz; Ken Herrmann; Christoph Rischpler; Frank Weber; Walter Jentzen; Sarah Theurer; Thorsten D Poeppel; Nicole Unger; Wolfgang P Fendler
Journal:  J Nucl Med       Date:  2021-09-23       Impact factor: 11.082

8.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

9.  I-124 Imaging and Dosimetry.

Authors:  Russ Kuker; Manuel Sztejnberg; Seza Gulec
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

Review 10.  Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning.

Authors:  Marcelo Tatit Sapienza; José Willegaignon
Journal:  Clinics (Sao Paulo)       Date:  2019-07-29       Impact factor: 2.365
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.